Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma

Thomas Powles(Queen Mary University of London), Noah M. Hahn(Johns Hopkins University), Peter H. O’Donnell(University of Chicago), Michael Ong(Ottawa Hospital), Srikala S. Sridhar(Princess Margaret Cancer Centre), Nicholas J. Vogelzang(Comprehensive Cancer Centers of Nevada), Jae‐Lyun Lee(Ulsan College), Christopher Hoimes(Duke Medical Center), Joyce Antal, Mayer Fishman(Moffitt Cancer Center), Terence W. Friedlander(University of California, San Francisco), Jingsong Zhang(Moffitt Cancer Center), Hendrik-Tobias Arkenau(University College London), Sandy Srinivas(Stanford University), Yong Ben(AstraZeneca (United States)), Christophe Massard(Institut Gustave Roussy), Ashok Gupta, Xiaoping Jin, Jigar Parikh(Augusta University)
JAMA Oncology
August 17, 2017
10.1001/jamaoncol.2017.2411
Cited by 846

Related Papers

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Nivolumab plus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2013|4.2k
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|3.7k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k